Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.36 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790841 | 1.00 | DUT (0.36) | DUTTOP2AFKBP1ANLRP3 | |
| SCHEMBL24854659 | 0.84 | NFKB1 (0.39) | DUTTOP2AFKBP1ANLRP3 | |
| SCHEMBL17019777 | 0.78 | DUT (0.34) | DUTTOP2A | |
| SCHEMBL10750836 | 0.76 | DUT (0.32) | DUT | |
| SCHEMBL10750827 | 0.76 | DUT (0.32) | DUT | |
| SCHEMBL4417335 | 0.73 | NFKB1 (0.30) | — | |
| SCHEMBL2953173 | 0.73 | NFKB1 (0.30) | — | |
| SCHEMBL5613785 | 0.73 | NFKB1 (0.30) | — | |
| SCHEMBL18187861 | 0.73 | DUT (0.35) | DUTTOP2A | |
| SCHEMBL18187862 | 0.73 | DUT (0.35) | DUTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396953-B2 | Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7396953-B2 | Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-07-08 | — | — | US | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1763500-A1 | NOVEL ANGIOGENESIS INHIBITORS AND PHARMACEUTICAL AND COSMETIC USE THEREOF | Galderma Research & Development, S.N.C. (FR) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006010859-A1 | NOVEL ANGIOGENESIS INHIBITORS AND PHARMACEUTICAL AND COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | FLT1, VEGFA, FGF1 | DUT 1967/4885TOP2A 3125/4885FKBP1A 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.